CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*
Key Study Slidesets Now Available!
Download these capsule summary slidesets highlighting key studies from the 2023 ASCO Gastrointestinal Cancers Symposium. Feel free to use and share some or all of these slides in your presentations to colleagues or patients.
- Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations
- Concordance Analysis of Gastric and Breast Cancer HER2 Scoring Systems for mCRC From the MOUNTAINEER Phase II Trial
- CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma
- CheckMate 649 Update: Phase III Study of First-line Nivolumab + CT vs CT for Advanced Gastric/GEJ Cancer and Esophageal Adenocarcinoma
- SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer
- LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer
- SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma
- SWOG 1815: Phase III Trial of First-line Gemcitabine/Cisplatin ± Nab-Paclitaxel for Advanced Biliary Tract Cancers
- NAPOLI 3: Phase III Trial of First-line NALIRIFOX vs Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Adenocarcinoma
An installment in the educational program:
CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*